A carregar...
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
BACKGROUND: Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway, the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ERα)...
Na minha lista:
Publicado no: | BMC Cancer |
---|---|
Main Authors: | , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5073873/ https://ncbi.nlm.nih.gov/pubmed/27765027 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2847-3 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|